

Weekly U.S. Influenza Surveillance Report | Seasonal Influenza (Flu) | CDC

Weekly U.S. Influenza Surveillance Report



2017-2018 Influenza Season Week 13 ending March 31, 2018

All data are preliminary and may change as more reports are received.

Synopsis:

During week 13 (March 25-31, 2018), influenza activity decreased in the United States.

- **[Viral Surveillance:](#)** Overall, influenza A(H3) viruses have predominated this season. Since early March, influenza B viruses have been more frequently reported than influenza A viruses. The percentage of respiratory specimens testing positive for influenza in clinical laboratories remains elevated.
- **[Pneumonia and Influenza Mortality:](#)** The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.
- **[Influenza-associated Pediatric Deaths:](#)** Five influenza-associated pediatric deaths were reported.
- **[Influenza-associated Hospitalizations:](#)** A cumulative rate of 99.9 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported.
- **[Outpatient Illness Surveillance:](#)** The proportion of outpatient visits for influenza-like illness (ILI) was 2.4%, which is above the national baseline of 2.2%. Seven of 10 regions reported ILI at or above region-specific baseline levels. Two states experienced high ILI activity; eight states experienced moderate ILI activity; New York City and 12 states experienced low ILI activity; and the District of Columbia, Puerto Rico, and 28 states experienced minimal ILI activity.
- **[Geographic Spread of Influenza:](#)** The geographic spread of influenza in 11 states was reported as widespread; Guam, Puerto Rico and 26 states reported regional activity; the District of Columbia and 10 states reported local activity; and the U.S. Virgin Islands and three states reported sporadic activity.

National and Regional Summary of Select Surveillance Components

HHS Surveillance Regions*	Data for current week			Data cur
	Out-patient ILI†	Number of jurisdictions reporting regional or widespread activity§	% respiratory specimens positive for flu in clinical laboratories‡	A(H1N1) Influenza
Nation	Elevated	39 of 54	15.4%	4,976
Region 1	Elevated	6 of 6	16.5%	274
Region 2	Normal	3 of 4	13.8%	284
Region 3	Elevated	4 of 6	15.4%	999
Region 4	Elevated	4 of 8	11.4%	835
Region 5	Elevated	5 of 6	22.8%	756
Region 6	Normal	1 of 5	7.3%	352
Region 7	Elevated	4 of 4	12.4%	82
Region 8	Normal	6 of 6	14.2%	294
Region 9	Elevated	3 of 5	10.9%	723
Region 10	Elevated	3 of 4	18.8%	377

*<https://www.hhs.gov/about/agencies/iea/regional-offices/index.html>

† Elevated means the % of visits for ILI is at or above the national or region-specific baseline

§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands

‡ National data are for current week; regional data are for the most recent three weeks

U.S. Virologic Surveillance:

WHO and NREVSS collaborating laboratories, which include both public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of Columbia, report to CDC the total number of respiratory specimens tested for influenza and the number positive for influenza by virus type. In addition, public health laboratories also report the influenza A subtype (H1 or H3) and influenza B lineage information of the viruses they test and the age or


age group of the persons from whom the specimens were collected.

Additional virologic data, including national, regional and select state-level data, can be found at: <http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>. Age group proportions and totals by influenza subtype reported by public health laboratories can be found at: http://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html.

The results of tests performed by clinical laboratories are summarized below.

	Week 13	Data Cumulative since October 1, 2017 (Week 40)
No. of specimens tested	21,823	1,073,126
No. of positive specimens (%)	3,357 (15.4%)	211,428 (19.7%)
<i>Positive specimens by type</i>		
Influenza A	1,329 (39.6%)	147,096 (69.6%)
Influenza B	2,028 (60.4%)	64,332 (30.4%)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2017-2018 Season



[View National and Regional Level Graphs and Data](#) | [View Chart Data](#)(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoAllregt_cl13.html) | [View Full Screen](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/WhoNPHL13.html)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/WhoNPHL13.html>) | [View PowerPoint Presentation](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)


The results of tests performed by public health laboratories, as well as the age group distribution of influenza positive tests, during the current week are summarized below.

	Week 13	Data Cumulative since October 1, 2017 (Week 40)
No. of specimens tested	775	86,725
	313	48,344

No. of positive specimens*		
<i>Positive specimens by type/subtype</i>		
Influenza A	120 (38.3%)	35,934 (74.3%)
A(H1N1)pdm09	41 (34.2%)	4,976 (13.8%)
H3N2	73 (60.8%)	30,378 (84.5%)
Subtyping not performed	6 (5.0%)	580 (1.6%)
Influenza B	193 (61.7%)	12,410 (25.7%)
Yamagata lineage	113 (58.5%)	8,297 (66.9%)
Victoria lineage	19 (9.8%)	974 (7.8%)
Lineage not performed	61 (31.6%)	3,139 (25.3%)


*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity. Additional information is available at <http://www.cdc.gov/flu/weekly/overview.htm>.

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2017-2018 Season



[View National and Regional Level Graphs and Data](#) | [View Chart](#)
[Data\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoAllregt_phl13.html\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoAllregt_phl13.html) |
[View Full Screen\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/WhoPHL13.html\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/WhoPHL13.html)
[View PowerPoint Presentation\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt)
<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoagesbar13.html>
<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoagesbar13.html>
<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/whoagesbar13.html>

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, Age Groups by Type and Subtype, 2017-2018 Season



(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/Whoageshorizontal13.html>)
[View Interactive Application](#) | [View Full Screen](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/Whoageshorizontal13.html>)

Influenza Virus Characterization:

Close monitoring of influenza viruses is required to better assess the potential impact on public health. CDC characterizes influenza viruses through one or more tests including [genomic sequencing](#) and [hemagglutination inhibition \(HI\)](#) (i.e., hemagglutination inhibition (HI) and/or neutralization assays). These data are used to monitor for changes in circulating influenza viruses and to compare how similar currently circulating influenza viruses are to the reference viruses used for developing influenza vaccines. Antigenic and genetic characterization of circulating influenza viruses can give an indication of the influenza vaccine's ability to produce an immune response against the wide array of influenza viruses co-circulating, but annual [vaccine effectiveness estimates](#) are needed to determine how much protection has been provided to the population by vaccination. On February 15, 2018, interim influenza vaccine effectiveness estimates for the 2017-2018 season were released and are available [here](#).

For nearly all influenza-positive surveillance samples received at CDC, next-generation sequencing is performed to determine the genetic identity of circulating influenza viruses and to monitor viruses for evidence of genetic changes. Viruses are classified into genetic clades/subclades based on analysis of the genetic sequences of the HA gene segments. However, genetic changes do not always result in antigenic change. Extensive genetic variation may exist in circulating viruses, with no evidence of substantial antigenic drift. Antigenic drift is evaluated by comparing cell-propagated circulating viruses with cell-propagated reference viruses representing currently recommended vaccine components.

CDC has antigenically or genetically characterized 2,422 influenza viruses collected during October 1, 2017 – March 31, 2018, and submitted by U.S. laboratories, including 589 influenza A(H1N1)pdm09 viruses, 1,053 influenza A(H3N2) viruses, and 780 influenza B viruses.

Influenza A Viruses


- **A (H1N1)pdm09:** Phylogenetic analysis of the HA genes from 589 A(H1N1)pdm09 viruses showed that all belonged to clade 6B.1. Four hundred ninety-seven A(H1N1)pdm09 viruses were antigenically characterized, and all were antigenically similar (analyzed using HI with ferret antisera) to the reference 6B.1 virus A/Michigan/45/2015, representing the recommended influenza A(H1N1)pdm09 reference virus for the 2017–18 Northern Hemisphere influenza vaccines.
- **A (H3N2):** Phylogenetic analysis of the HA genes from 1,053 A(H3N2) viruses revealed extensive genetic diversity with multiple clades/subclades co-circulating. The HA genes of circulating viruses belonged to clade 3C.2a (n=883), subclade 3C.2a1 (n=131) or clade 3C.3a (n=39). Five hundred eleven influenza A(H3N2) viruses were antigenically characterized, and 495 (96.9%) A(H3N2) viruses tested were well-inhibited (reacting at titers that were within fourfold of the homologous virus titer) by ferret antisera raised against A/Michigan/15/2014 (3C.2a), a cell-propagated A/Hong Kong/4801/2014-like reference virus representing the A(H3N2) component of the 2017–18 Northern Hemisphere influenza vaccines.

Influenza B Viruses

- **B/Victoria:** Phylogenetic analysis of 158 B/Victoria-lineage viruses indicate that all HA genes belonged to genetic clade V1A, the same genetic clade as the vaccine reference virus, B/Brisbane/60/2008. However, a number of viruses had a 6-nucleotide deletion (encoding amino acids 162 and 163) in the HA (abbreviated as V1A-2Del). Thirty-seven (28.0%) B/Victoria lineage viruses were well-inhibited by ferret antisera raised against cell-propagated B/Brisbane/60/2008 reference virus, representing a recommended B virus component of the 2017–18 Northern Hemisphere influenza vaccines. Ninety-five (72.0%) B/Victoria lineage viruses reacted poorly (at titers that were 8-fold or greater reduced compared with the homologous virus titer) with ferret antisera raised against cell-propagated B/Brisbane/60/2008, and these viruses had the V1A-2Del HA.
- **B/Yamagata:** Phylogenetic analysis of 622 influenza B/Yamagata-lineage viruses indicate that the HA genes belonged to clade Y3. A total of 475 influenza B/Yamagata-

lineage viruses were antigenically characterized, and all were antigenically similar to cell propagated B/Phuket/3073/2013, the reference vaccine virus representing the influenza B/Yamagata-lineage component of the 2017–18 Northern Hemisphere quadrivalent vaccines.

The majority of U.S. viruses submitted for characterization come from state and local public health laboratories. Due to [Right Size Roadmap](#) considerations, specimen submission guidance to laboratories is that, if available, 2 influenza A(H1N1)pdm09, 2 influenza A(H3N2), and 2 influenza B viruses be submitted every other week. Therefore, the numbers of each virus type/subtype characterized should be more balanced across subtypes/lineages but will not reflect the actual proportion of circulating viruses. In the figure below, the results of tests performed by public health labs are shown on the left and CDC sequence results (by genetic clade/subclade) are shown on the right.



[View Chart Data\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/Genetic13.csv\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/Genetic13.csv) | [View Full Screen\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/Genetic13.html\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/Genetic13.html) | [View PowerPoint Presentation\(https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt\)](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt)

2018-2019 Influenza Season – U.S. Influenza Vaccine Composition:

The World Health Organization (WHO) has recommended the Northern Hemisphere 2018-2019 influenza vaccine composition, and the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) subsequently made the influenza vaccine composition recommendation for the United States. Both agencies recommend that influenza trivalent vaccines contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus, and a B/Colorado/06/2017-like (B/Victoria lineage) virus. It is recommended that quadrivalent vaccines, which have two influenza B viruses, contain the viruses recommended for the trivalent vaccines, as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus. The B recommendation represents a change in the influenza B/Victoria lineage component recommended for the 2017-2018 Northern Hemisphere and 2018 Southern Hemisphere influenza vaccines. The H3N2 recommendation represents an update to the 2017-2018 Northern Hemisphere vaccines, but not to the 2018 Southern Hemisphere vaccines which were recommended to include A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus. The B component change was made because of the detection and increasing global circulation of an antigenically drifted B/Victoria lineage virus. The update to the H3N2 component is not a result of antigenic drift, but because the egg-propagated A/Singapore vaccine virus is antigenically more similar to circulating viruses than the egg-propagated A/Hong Kong vaccine virus recommended for the Northern Hemisphere 2017-2018 vaccines. These vaccine recommendations were based on several factors, including global influenza virologic and epidemiologic surveillance, genetic characterization, antigenic characterization and the candidate vaccine viruses that are available for production.

Antiviral Resistance:

Testing of influenza A (H1N1)pdm09, influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is performed at CDC using a functional assay. Additional influenza A (H1N1)pdm09 and influenza A (H3N2) viruses from clinical samples are tested for mutations known to confer oseltamivir resistance. The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A (H1N1)pdm09 and influenza A (H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, data from adamantane resistance testing are not presented below.

Neuraminidase Inhibitor Resistance

**Testing
Results on
Samples
Collected
Since October
1, 2017**

Oseltamivir Zanamivir Peramivir

Influenza A (H1N1)pdm09 841 9 (1.1) 568 0 (0.0) 841 9 (1.1)

Influenza A (H3N2) 1,739 0 (0.0) 1,739 0 (0.0) 1,009 0 (0.0)

Influenza B 752 0 (0.0) 752 0 (0.0) 752 0 (0.0)

On December 27, 2017, a Health Advisory was released by CDC providing: 1) a notice about increased influenza A(H3N2) activity and its clinical implications; 2) a summary of influenza antiviral drug treatment recommendations; 3) an update about approved treatment drugs and supply this season; and 4) background information for patients about influenza treatment. More information is available at <https://emergency.cdc.gov/han/han00409.asp>.

The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of oseltamivir-resistant and peramivir-resistant influenza A(H1N1)pdm09 viruses and oseltamivir-resistant influenza A(H3N2) viruses have been detected worldwide. Antiviral treatment as early as possible is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at [high risk](#) for serious influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at <http://www.cdc.gov/flu/antivirals/index.htm>.


[Pneumonia and Influenza \(P&I\) Mortality Surveillance:](#)

Based on National Center for Health Statistics (NCHS) mortality surveillance data available on April 5, 2018, 7.1% of the deaths occurring during the week ending March 17, 2018 (week 11) were due to P&I. This percentage is below the epidemic threshold of 7.3% for week 11.

Background: Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths

due to P&I are higher among manually coded records than more rapidly available machine coded records. There is currently a delay in manual coding for deaths occurring in 2018. Because of this delay initially reported P&I percentages will be lower than those calculated from the final data.

Region and state-specific data are available at <http://gis.cdc.gov/grasp/fluview/mortality.html>.



[View Regional and State Level Data](#) | [View Chart Data](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/NCHSData13.csv>) | [View Full Screen](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/NCHS13.html)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/NCHS13.html>) | [View PowerPoint Presentation](https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)


Influenza-Associated Pediatric Mortality:

Five influenza-associated pediatric deaths were reported to CDC during week 13. One death was associated with an influenza A(H3) virus and occurred during week 13 (the week ending March 31, 2018). Two deaths were associated with an influenza A virus for which subtyping was not performed and occurred during weeks 9 and 12 (the week ending March 3 and March 24, 2018, respectively). Two deaths were associated with an influenza B virus and

occurred during weeks 12 and 13 (the weeks ending March 24 and March 31, 2018, respectively).

A total of 142 influenza-associated pediatric deaths have been reported for the 2017-2018 season.

Additional data can be found at: <http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html>.



[View Interactive Application](#) | [View Full Screen](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/PedFlu13.html>) | [View PowerPoint Presentation](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)

[Influenza-Associated Hospitalizations:](#)

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) and adults (since the 2005-2006 influenza season).

The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP)

states (CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and additional Influenza Hospitalization Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT during the 2011-2012 season; IA, MI, OH, RI, and UT during the 2012-2013 season; and MI, OH, and UT during the 2013-2014, 2014-15, 2015-16, 2016-17, and 2017-18 seasons.

Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and describe characteristics of persons hospitalized with influenza illness. The rates provided are likely to be an underestimate as influenza-related hospitalizations can be missed, either because testing is not performed, or because cases may be attributed to other causes of pneumonia or other common influenza-related complications.


A total of 28,543 laboratory-confirmed influenza-associated hospitalizations were reported between October 1, 2017 and March 31, 2018. The overall hospitalization rate was 99.9 per 100,000 population. The highest rate of hospitalization was among adults aged ≥ 65 years (429.4 per 100,000 population), followed by adults aged 50-64 (108.7 per 100,000 population) and children aged 0-4 years (71.2 per 100,000 population). Among 28,543 hospitalizations, 21,530 (75.4%) were associated with influenza A virus, 6,835 (23.9%) with influenza B virus, 101 (0.4%) with influenza A virus and influenza B virus co-infection, and 77 (0.3%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 5,456 (85.0%) were A(H3N2) and 961 (15.0%) were A(H1N1)pdm09 virus.

Among 3,446 hospitalized adults with information on underlying medical conditions, 3,206 (93.0%) had at least one reported underlying medical condition; the most commonly reported were cardiovascular disease, metabolic disorder, obesity, and chronic lung disease. Among 309 hospitalized children with information on underlying medical conditions, 169 (54.7%) had at least one underlying medical condition; the most commonly reported were asthma, neurologic disorder, and obesity. Among 253 hospitalized women of childbearing age (15-44 years) with information on pregnancy status, 77 (30.4%) were pregnant.

Additional FluSurv-NET data can be found at:
<http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html> and
<http://gis.cdc.gov/grasp/fluview/FluHospChars.html>.


Laboratory-Confirmed Influenza Hospitalizations

Preliminary cumulative rates as of Mar 31, 2018



Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza related hospitalizations in children and adults in 13 U.S. states. Cumulative incidence rates are calculated using the National Center for Health Statistics' (NCHS) population estimates for the counties included in the surveillance catchment area.

[View Interactive Application](#) | [View Full Screen](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/EIPrates13.html>) | [View PowerPoint Presentation](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)




FluSurv-NET data are preliminary and displayed as they become available. Therefore, figures are based on varying denominators as some variables represent information that may require more time to be collected. Data are refreshed and updated weekly. Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart failure, and pulmonary hypertension; does not include isolated hypertension; Chronic lung diseases include conditions such as chronic obstructive pulmonary disease, bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease; Immune suppression includes conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications; Metabolic disorders include conditions such as diabetes mellitus; Neurologic diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction; Neuromuscular diseases include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if indicated in patient's medical chart or if body mass index (BMI) >30 kg/m²; Pregnancy percentage calculated using number of female cases aged between 15 and 44 years of age as the denominator; Renal diseases include conditions such as acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance; No known condition indicates that the case did not have any known high risk medical condition indicated in medical chart at the time of hospitalization.

[View Interactive Application](#) | [View Full Screen](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/EIPConditions13.html>) | [View PowerPoint Presentation](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)

Outpatient Illness Surveillance:

Nationwide during week 13, 2.4% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is above the national baseline of 2.2%. (ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.)

Additional ILINet data, including national, regional and select state-level data, are available at <http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>.



[View National and Regional Level Graphs and Data](#) | [View Chart Data](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/data/senAllregt13.html>) | [View Full Screen](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/ILI13.html>) | [View PowerPoint Presentation](#)(<https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/FluView13.ppt>)

On a regional level, the percentage of outpatient visits for ILI ranged from 1.1% to 2.9% during week 13. Seven of ten 10 regions (Regions 1, 3, 4, 5, 7, 9, and 10) reported percentages of outpatient visits for ILI at or above their region-specific baselines.

ILINet State Activity Indicator Map:

Data collected in ILINet are used to produce a measure of ILI activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI and are compared to the average percent of ILI visits that occur during weeks with little or no influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity from outpatient clinics being below, or only slightly above, the average, to high, which would correspond to ILI activity from outpatient clinics being much higher than average.

During week 13, the following ILI activity levels were experienced:

- Two states experienced high ILI activity (Alaska and Virginia).
- Eight states experienced moderate ILI activity (Arizona, Kentucky, Michigan, Nebraska, North Carolina, South Carolina, South Dakota, and Wyoming).
- New York City and 12 states experienced low ILI activity (California, Georgia, Indiana, Kansas, Massachusetts, Minnesota, New Jersey, New Mexico, Oregon, Pennsylvania, Vermont, and West Virginia).
- The District of Columbia, Puerto Rico, and 28 states experienced minimal ILI activity (Alabama, Arkansas, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Iowa, Louisiana, Maine, Maryland, Mississippi, Missouri, Montana, Nevada, New Hampshire, New York, North Dakota, Ohio, Oklahoma, Rhode Island, Tennessee, Texas, Utah, Washington, and Wisconsin).

Click on map to launch interactive tool

*This map uses the proportion of outpatient visits to health care providers for ILI to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.

Data collected in ILINet may disproportionately represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state.

Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports from state and territorial epidemiologists. The data presented in this map are preliminary and may change as more data are received. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses, but does not measure the severity of influenza activity.

Additional data can be found at <https://gis.cdc.gov/grasp/fluview/FluView8.html>.

During week 13, the following influenza activity was reported:

- Widespread influenza activity was reported by 11 states (California, Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New York, Ohio, Rhode Island, Virginia, and Wisconsin).
- Regional influenza activity was reported by Guam, Puerto Rico and 26 states (Alaska, Arizona, Colorado, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Michigan, Missouri, Montana, Nebraska, New Jersey, North Carolina, North Dakota, Oklahoma, Pennsylvania, South Carolina, South Dakota, Utah, Vermont, Washington, and Wyoming).
- Local influenza activity was reported by the District of Columbia and 10 states (Arkansas, Georgia, Hawaii, Louisiana, Minnesota, Nevada, New Mexico, Oregon, Texas, and West Virginia).
- Sporadic influenza activity was reported by the U.S. Virgin Islands and three states (Alabama, Tennessee, and Mississippi).

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit <http://www.cdc.gov/flu/weekly/fluviewinteractive.htm>.

U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information.

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through [FluNet](#) and the [Global Epidemiology Reports](#).

WHO Collaborating Centers for Influenza located in [Australia](#), [China](#), [Japan](#), the [United Kingdom](#), and the [United States](#) (CDC in Atlanta, Georgia).

Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European Centre for Disease Prevention and Control at <http://www.flunewseurope.org/>.

Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at <http://www.phac-aspc.gc.ca/fluwatch/>

Public Health England: The most up-to-date influenza information from the United Kingdom is available at <https://www.gov.uk/government/statistics/weekly-national-flu-reports>

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at:
<http://www.cdc.gov/flu/weekly/overview.htm>.
